JO3040B1 - ترايازولوبيريدينات - Google Patents
ترايازولوبيريديناتInfo
- Publication number
- JO3040B1 JO3040B1 JOP/2012/0093A JOP20120093A JO3040B1 JO 3040 B1 JO3040 B1 JO 3040B1 JO P20120093 A JOP20120093 A JO P20120093A JO 3040 B1 JO3040 B1 JO 3040B1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- triazolopyridines
- prophylaxis
- disease
- preparing
- Prior art date
Links
- 150000008523 triazolopyridines Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
يتعلق الاختراع الحالي بمركبات triazolopyridine من الصيغة العامة (I): (I) حيث R1، R2، R3، R4، وR5 كما هو موضح في الوصف وفي عناصر الحماية، بطرق لتحضير المركبات المذكورة، بتركيبات دوائية واتحادات تشمل المركبات المذكورة، باستخدام المركبات المذكورة لتصنيع تركيبة دوائية لمعالجة أو الوقاية من مرض، بالإضافة إلى مركبات وسطية مفيدة في تحضير المركبات المذكورة.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11163342 | 2011-04-21 | ||
| EP11167872 | 2011-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3040B1 true JO3040B1 (ar) | 2016-09-05 |
Family
ID=46124297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2012/0093A JO3040B1 (ar) | 2011-04-21 | 2012-04-18 | ترايازولوبيريدينات |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US20140120087A1 (ar) |
| EP (1) | EP2699575B1 (ar) |
| JP (1) | JP5989091B2 (ar) |
| KR (1) | KR20140025470A (ar) |
| CN (1) | CN103608350B (ar) |
| AP (1) | AP3491A (ar) |
| AR (1) | AR086191A1 (ar) |
| AU (1) | AU2012244859B2 (ar) |
| CA (1) | CA2833657A1 (ar) |
| CL (1) | CL2013003044A1 (ar) |
| CO (1) | CO6801751A2 (ar) |
| CR (1) | CR20130539A (ar) |
| CY (1) | CY1116439T1 (ar) |
| DK (1) | DK2699575T3 (ar) |
| DO (1) | DOP2013000244A (ar) |
| EA (1) | EA023766B1 (ar) |
| EC (1) | ECSP13013011A (ar) |
| ES (1) | ES2539265T3 (ar) |
| GT (1) | GT201300254A (ar) |
| HR (1) | HRP20150517T1 (ar) |
| HU (1) | HUE025496T2 (ar) |
| IL (1) | IL228704A0 (ar) |
| JO (1) | JO3040B1 (ar) |
| MA (1) | MA35049B1 (ar) |
| ME (1) | ME02143B (ar) |
| MX (1) | MX348783B (ar) |
| MY (1) | MY164939A (ar) |
| PE (1) | PE20141351A1 (ar) |
| PH (1) | PH12013502169A1 (ar) |
| PL (1) | PL2699575T3 (ar) |
| PT (1) | PT2699575E (ar) |
| RS (1) | RS54044B1 (ar) |
| SA (1) | SA112330466B1 (ar) |
| SG (1) | SG194003A1 (ar) |
| SI (1) | SI2699575T1 (ar) |
| TW (1) | TWI558703B (ar) |
| UY (1) | UY34034A (ar) |
| WO (1) | WO2012143329A1 (ar) |
| ZA (1) | ZA201308707B (ar) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111841C2 (uk) | 2011-04-21 | 2016-06-24 | Гіліад Сайєнсіз, Інк. | Сполуки бензотіазолу та їх фармацевтичне застосування |
| UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| WO2013103738A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
| US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
| JP6166289B2 (ja) | 2012-03-14 | 2017-07-19 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリダジン |
| BR112015000308A2 (pt) | 2012-07-10 | 2017-06-27 | Bayer Pharma AG | método para preparo de triazolopiridinas substituídas |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| CA2914521A1 (en) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines having activity as mps-1 inhibitors |
| CA2914516A1 (en) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines |
| CN105246891A (zh) * | 2013-06-10 | 2016-01-13 | 拜耳制药股份公司 | 用于治疗癌症的新化合物 |
| EP3007692A1 (en) * | 2013-06-11 | 2016-04-20 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
| PE20160156A1 (es) | 2013-06-11 | 2016-04-20 | Bayer Pharma AG | Derivados de prodroga de triazolpiridinas sustituidas |
| EP2860177A3 (en) | 2013-09-20 | 2015-06-10 | Bayer Intellectual Property GmbH | Synthesis of functionalized arenes |
| EP3283642B1 (en) | 2015-04-17 | 2023-10-11 | Netherlands Translational Research Center Holding B.V. | Prognostic biomarkers for ttk inhibitor chemotherapy |
| WO2018166493A1 (zh) * | 2017-03-16 | 2018-09-20 | 江苏恒瑞医药股份有限公司 | 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
| NZ780966A (en) | 2019-04-18 | 2026-02-27 | Univ Johns Hopkins | Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof |
| JP2022539208A (ja) | 2019-07-03 | 2022-09-07 | スミトモ ファーマ オンコロジー， インコーポレイテッド | チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用 |
| IL301817A (en) | 2020-10-13 | 2023-06-01 | Univ Johns Hopkins | Modified 4-([4,2,1]triazolo[5,1-a]pyridin-6-yl)thiophene-2-carboxamide histories and their use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| RU2007109778A (ru) | 2004-08-17 | 2008-09-27 | Галдерма Ресерч Энд Девелопмент, С.Н.С. (Fr) | Новые биароматические соединения, которые активируют рецепторы типа ppar, и их применение в косметических и фармацевтических композициях |
| ES2549862T3 (es) * | 2006-08-30 | 2015-11-02 | Cellzome Limited | Derivados de triazol como inhibidores de quinasa |
| EP2178868A1 (en) * | 2007-07-18 | 2010-04-28 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| MX2010002115A (es) | 2007-08-23 | 2010-06-01 | Aztrazeneca Ab | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. |
| MX2010002312A (es) | 2007-08-31 | 2010-03-18 | Merck Serono Sa | Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis. |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP2222674B8 (en) * | 2007-11-27 | 2016-01-06 | Cellzome Limited | Amino triazoles as pi3k inhibitors |
| CN102317288A (zh) * | 2009-02-13 | 2012-01-11 | 佛维雅制药公司 | 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶 |
| ES2547328T3 (es) | 2009-04-29 | 2015-10-05 | Bayer Intellectual Property Gmbh | Imidazoquinoxalinas sustituidas |
| JP5728683B2 (ja) | 2009-09-04 | 2015-06-03 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン |
| EP2343297A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
-
2012
- 2012-04-16 US US14/113,017 patent/US20140120087A1/en not_active Abandoned
- 2012-04-16 CA CA2833657A patent/CA2833657A1/en not_active Abandoned
- 2012-04-16 EA EA201301181A patent/EA023766B1/ru not_active IP Right Cessation
- 2012-04-16 HU HUE12721779A patent/HUE025496T2/en unknown
- 2012-04-16 SG SG2013073044A patent/SG194003A1/en unknown
- 2012-04-16 SI SI201230220T patent/SI2699575T1/sl unknown
- 2012-04-16 DK DK12721779.2T patent/DK2699575T3/da active
- 2012-04-16 KR KR1020137030546A patent/KR20140025470A/ko not_active Ceased
- 2012-04-16 PH PH1/2013/502169A patent/PH12013502169A1/en unknown
- 2012-04-16 PE PE2013002378A patent/PE20141351A1/es not_active Application Discontinuation
- 2012-04-16 AU AU2012244859A patent/AU2012244859B2/en not_active Ceased
- 2012-04-16 MX MX2013012289A patent/MX348783B/es active IP Right Grant
- 2012-04-16 RS RS20150345A patent/RS54044B1/sr unknown
- 2012-04-16 JP JP2014505584A patent/JP5989091B2/ja not_active Expired - Fee Related
- 2012-04-16 PL PL12721779T patent/PL2699575T3/pl unknown
- 2012-04-16 EP EP12721779.2A patent/EP2699575B1/en active Active
- 2012-04-16 AP AP2013007182A patent/AP3491A/xx active
- 2012-04-16 ME MEP-2015-80A patent/ME02143B/me unknown
- 2012-04-16 WO PCT/EP2012/056914 patent/WO2012143329A1/en not_active Ceased
- 2012-04-16 MY MYPI2013701964A patent/MY164939A/en unknown
- 2012-04-16 ES ES12721779.2T patent/ES2539265T3/es active Active
- 2012-04-16 HR HRP20150517TT patent/HRP20150517T1/hr unknown
- 2012-04-16 PT PT127217792T patent/PT2699575E/pt unknown
- 2012-04-16 CN CN201280030682.XA patent/CN103608350B/zh not_active Expired - Fee Related
- 2012-04-16 MA MA36344A patent/MA35049B1/fr unknown
- 2012-04-18 SA SA112330466A patent/SA112330466B1/ar unknown
- 2012-04-18 JO JOP/2012/0093A patent/JO3040B1/ar active
- 2012-04-20 AR ARP120101355A patent/AR086191A1/es unknown
- 2012-04-20 TW TW101114259A patent/TWI558703B/zh not_active IP Right Cessation
- 2012-04-20 UY UY0001034034A patent/UY34034A/es not_active Application Discontinuation
-
2013
- 2013-10-03 IL IL228704A patent/IL228704A0/en unknown
- 2013-10-18 GT GT201300254A patent/GT201300254A/es unknown
- 2013-10-21 CO CO13248763A patent/CO6801751A2/es active IP Right Grant
- 2013-10-21 DO DO2013000244A patent/DOP2013000244A/es unknown
- 2013-10-21 CR CR20130539A patent/CR20130539A/es unknown
- 2013-10-21 CL CL2013003044A patent/CL2013003044A1/es unknown
- 2013-11-05 EC ECSP13013011 patent/ECSP13013011A/es unknown
- 2013-11-20 ZA ZA2013/08707A patent/ZA201308707B/en unknown
-
2015
- 2015-06-12 CY CY20151100512T patent/CY1116439T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA112330466B1 (ar) | ترايازولوبيريدينات | |
| JO3111B1 (ar) | ترايازولوبيريدينات مستبدلة واستخدامها كمثبطات ttk | |
| TN2012000595A1 (en) | Substituted triazolopyridines | |
| TN2012000265A1 (en) | Triazolopyridines | |
| PH12013500454A1 (en) | Substituted imidazopyridazines | |
| TW201613874A (en) | Benzimidazol-2-amines as mIMH1 inhibitors | |
| MY168413A (en) | Amino-substituted imidazopyridazines | |
| IN2012DN02139A (ar) | ||
| MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| PH12016500054A1 (en) | Substituted pyrazolo-pyridinamines | |
| PH12015502747A1 (en) | Novel compounds for the treatment of cancer | |
| PH12015500061A1 (en) | Method for preparing substituted triazolopyridines | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| TN2013000426A1 (en) | Triazolopyridines | |
| SA112330437B1 (ar) | تركيبات دوائية محتوية على عامل منوم او مخدر وطريقة تحضيرها |